Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Weight reduction in schizophrenics by molindone

G Gardos, J O Cole

    The American Journal of Psychiatry
    |March 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Molindone, an antipsychotic, caused significant weight loss in schizophrenic patients. Average weight reduction was 7.6 kg over three months, possibly due to appetite suppression.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Long-term treatment of panic disorder with agoraphobia in private practice.

    Journal of psychiatric practice·2005
    Same author

    Clozapine in the treatment of refractory psychotic mania.

    The American journal of psychiatry·2000
    Same author

    Managing antipsychotic-induced tardive dyskinesia.

    Drug safety·1999
    Same author

    Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines.

    Journal of clinical psychopharmacology·1998
    Same author

    Reversible dyskinesia during bupropion therapy.

    The Journal of clinical psychiatry·1997
    Same author

    Description of antipanic therapy in a prospective longitudinal study.

    Journal of clinical psychopharmacology·1996
    Same journal

    2026 Annual Meeting: President-Elect Address.

    The American journal of psychiatry·2026
    Same journal

    2026 Annual Meeting: CEO and Medical Director's Address.

    The American journal of psychiatry·2026
    Same journal

    Reports to the Membership.

    The American journal of psychiatry·2026
    Same journal

    Convergent Metabolic Dysregulations But Divergent Contributing Pathways Across Severe Mental Disorders: The Power of Combining Genetics and Metabolomics.

    The American journal of psychiatry·2026
    Same journal

    2026 Annual Meeting: Presidential Address.

    The American journal of psychiatry·2026
    Same journal

    Represcribing Previously Used Antipsychotics: Response to So.

    The American journal of psychiatry·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Psychiatry

    Background:

    • Antipsychotic medications are often associated with weight gain.
    • Molindone is a recently introduced antipsychotic drug.

    Purpose of the Study:

    • To investigate the weight-reducing property of molindone.
    • To assess the effect of molindone on body weight in chronic schizophrenic patients.

    Main Methods:

    • A study was conducted on 9 hospitalized chronic schizophrenic patients.
    • Patients were treated with molindone for 3 months.

    Main Results:

    • An average weight loss of 7.6 kg was observed.
    • Most of the weight loss occurred within the first month of treatment.

    Related Experiment Videos

    Conclusions:

    • Molindone demonstrated a weight-reducing effect in chronic schizophrenic patients.
    • The mechanism may involve a central anorexigenic (appetite-suppressing) effect.